User login
Key clinical point: Secukinumab demonstrated high retention rates, sustained efficacy, and a favorable safety profile for at least 2 years after initiation in a real-world population of patients with moderate-to-severe psoriatic arthritis (PsA).
Major finding: Secukinumab showed high retention rates (74.9%) at > 2 years after initiation and a sustained improvement in the mean tender joint count (6.3 and 5.6, respectively) and swollen joint count (3.3 and 2.9, respectively) scores at baseline and 2 years. At least 1 serious adverse event was reported by 8.3% of patients, but no death was reported.
Study details: Findings are from a 2-year interim analysis of SERENA, an ongoing, longitudinal, observational study, including 1004 patients with moderate-to-severe PsA (n = 534) or ankylosing spondylitis (n = 470) who received secukinumab for 16 weeks prior recruitment.
Disclosures: This study was funded by Novartis Pharma AG. Three authors reported being employees or owning stocks in Novartis. Several authors reported receiving research grants, consulting fees, or speaker fees from various sources, including Novartis.
Source: Kiltz U et al. Interim 2-year analysis from SERENA: A real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther. 2022 (Jun 8). Doi: 10.1007/s40744-022-00460-x
Key clinical point: Secukinumab demonstrated high retention rates, sustained efficacy, and a favorable safety profile for at least 2 years after initiation in a real-world population of patients with moderate-to-severe psoriatic arthritis (PsA).
Major finding: Secukinumab showed high retention rates (74.9%) at > 2 years after initiation and a sustained improvement in the mean tender joint count (6.3 and 5.6, respectively) and swollen joint count (3.3 and 2.9, respectively) scores at baseline and 2 years. At least 1 serious adverse event was reported by 8.3% of patients, but no death was reported.
Study details: Findings are from a 2-year interim analysis of SERENA, an ongoing, longitudinal, observational study, including 1004 patients with moderate-to-severe PsA (n = 534) or ankylosing spondylitis (n = 470) who received secukinumab for 16 weeks prior recruitment.
Disclosures: This study was funded by Novartis Pharma AG. Three authors reported being employees or owning stocks in Novartis. Several authors reported receiving research grants, consulting fees, or speaker fees from various sources, including Novartis.
Source: Kiltz U et al. Interim 2-year analysis from SERENA: A real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther. 2022 (Jun 8). Doi: 10.1007/s40744-022-00460-x
Key clinical point: Secukinumab demonstrated high retention rates, sustained efficacy, and a favorable safety profile for at least 2 years after initiation in a real-world population of patients with moderate-to-severe psoriatic arthritis (PsA).
Major finding: Secukinumab showed high retention rates (74.9%) at > 2 years after initiation and a sustained improvement in the mean tender joint count (6.3 and 5.6, respectively) and swollen joint count (3.3 and 2.9, respectively) scores at baseline and 2 years. At least 1 serious adverse event was reported by 8.3% of patients, but no death was reported.
Study details: Findings are from a 2-year interim analysis of SERENA, an ongoing, longitudinal, observational study, including 1004 patients with moderate-to-severe PsA (n = 534) or ankylosing spondylitis (n = 470) who received secukinumab for 16 weeks prior recruitment.
Disclosures: This study was funded by Novartis Pharma AG. Three authors reported being employees or owning stocks in Novartis. Several authors reported receiving research grants, consulting fees, or speaker fees from various sources, including Novartis.
Source: Kiltz U et al. Interim 2-year analysis from SERENA: A real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther. 2022 (Jun 8). Doi: 10.1007/s40744-022-00460-x